A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection
Phase of Trial: Phase IV
Latest Information Update: 09 May 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 26 Oct 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 26 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.
- 26 Oct 2016 Status changed from not yet recruiting to recruiting.